2022
DOI: 10.1038/s41598-022-13968-7
|View full text |Cite
|
Sign up to set email alerts
|

Long-lasting reflexive and nonreflexive pain responses in two mouse models of fibromyalgia-like condition

Abstract: Nociplastic pain arises from altered nociception despite no clear evidence of tissue or somatosensory system damage, and fibromyalgia syndrome can be highlighted as a prototype of this chronic pain subtype. Currently, there is a lack of effective treatments to alleviate both reflexive and nonreflexive pain responses associated with fibromyalgia condition, and suitable preclinical models are needed to assess new pharmacological strategies. In this context, although in recent years some remarkable animal models … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
59
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

3
3

Authors

Journals

citations
Cited by 14 publications
(61 citation statements)
references
References 90 publications
(112 reference statements)
2
59
0
Order By: Relevance
“…Previous studies have shown that σ1R antagonists are able to modulate pathological pain in several preclinical models [ 21 ], but their potential modulatory effects on nociplastic pain remain to be investigated. To this end, an acute dose–response (15, 20, 25, 40, or 60 mg/kg) method was designed to determine whether the σ1R antagonist BD1063 exerts antinociceptive effects in two fibromyalgia-like models with long-lasting nociplastic pain: reserpine-induced myalgia RIM6 mice [ 7 , 28 ] and intramuscular acid saline solution injection ASI mice [ 7 , 29 ]. Withdrawal latency to thermal stimulation was assessed immediately before (preadministration) and 30 min after (postadministration) compound treatment.…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…Previous studies have shown that σ1R antagonists are able to modulate pathological pain in several preclinical models [ 21 ], but their potential modulatory effects on nociplastic pain remain to be investigated. To this end, an acute dose–response (15, 20, 25, 40, or 60 mg/kg) method was designed to determine whether the σ1R antagonist BD1063 exerts antinociceptive effects in two fibromyalgia-like models with long-lasting nociplastic pain: reserpine-induced myalgia RIM6 mice [ 7 , 28 ] and intramuscular acid saline solution injection ASI mice [ 7 , 29 ]. Withdrawal latency to thermal stimulation was assessed immediately before (preadministration) and 30 min after (postadministration) compound treatment.…”
Section: Resultsmentioning
confidence: 99%
“…The effect of BD1063 administered twice a day (i.p. ; 6 h between administrations) at 40 mg/kg during 2 weeks after fibromyalgia-like induction was compared with the effect of pregabalin, an FDA-approved drug for fibromyalgia syndrome treatment [ 35 , 36 ], administered once a day at 20 mg/kg, a dose that exerts maximum antinociceptive effects in either RIM6 or ASI models, according to a recent dose–response study in our laboratory [ 7 ]. Thermal hyperalgesia was evaluated weekly on a long-term basis, extending to several weeks after the discontinuation of the 2-week treatment.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations